Copanlisib Pharmacodynamic Study

• Status: Completed
• Trial end date: 2017-03-16

Summary

This study aims to analyze what the study drug does to the body and its relationship to drug levels and safety after patients with advanced cancer have been treated with copanlisib in different dose groups.

• Phase: Phase 1

Details

• Lead Sponsor: Bayer